ACCREDITATION STATUS:

UKAS accredited - Proficiency testing provider No. 7804

This programme is operated by UK NEQAS Leucocyte Immunophenotyping. The centre provides flow cytometry and molecular haematology based programmes. For further information on the operation of the programme or details on current accreditation status please contact UK NEQAS Leucocyte Immunophenotyping directly.

Email: admin@ukneqasli.co.uk

Telephone: +44 (0) 114 267 3600

CLINICAL APPLICATION:

Mutations in the NPM1 gene are diagnostic/prognostic markers in Acute Myeloid Leukaemia.

PURPOSE OF PROGRAMME:

To assess a laboratories ability to accurately detect the NPM1 Mutation Status using molecular methods. NPM1 mutation load will reflect levels seen at diagnosis.

ANALYTES:

Analyte	Default Unit
npm1

PROGRAMME OF ANALYSIS:

Results are entered online via the UK NEQAS LI website. Trials are live for 4 weeks. If you are unable to complete your trial analysis within the specified period please contact admin@ukneqasli.co.uk

DATA ANALYSIS:

This programme is a qualitative scheme and so participants should answer 'mutation detected' or 'no mutation detected' to indicate the presence or absence of a NPM1 mutation in each sample and if positive the type of mutation detected. The presence/absence of the NPM1 mutation is determined from the consensus of all participants' results (modal result).

PERFORMANCE SCORING:

The scoring system is a rolling scheme that will identify unsatisfactory performance or persistent unsatisfactory performance of any participant. This is in order that UK NEQAS LI can provide support and guidance where needed, and ensure that the Genetics NQAAP are informed as appropriate. Please note that each programme will be scored independently. Each participant response is then compared against the consensus results. If the participant is out of consensus for one or both sample(s) a Criti

PERFORMANCE MONITORING:

If a participant is awarded two Critical statuses out of three trials issued, then their overall status will escalate to persistent unsatisfactory performance. If a participant's status is elevated to persistent unsatisfactory performance then a further letter will be issued highlighting this and, for UK based laboratories, the Genetics NQAAP panel informed.